Abstract
The γ-secretase aspartyl protease is responsible for the cleavage of numerous type I integral membrane proteins, including amyloid precursor protein (APP) and Notch. APP cleavage contributes to the generation of toxic amyloid β peptides in Alzheimer's disease, whereas cleavage of the Notch receptor is required for normal physiological signaling between differentiating cells. Mutagenesis studies as well as in vivo analyses of Notch and APP activity in the presence of pharmacological inhibitors indicate that these substrates can be differentially modulated by inhibition of mammalian γ-secretase, although some biochemical studies instead show nearly identical dose-response inhibitor effects on Notch and APP cleavages. Here, we examine the dose-response effects of several inhibitors on Notch and APP in Drosophila melanogaster cells, which possess a homogeneous form of γ-secretase. Four different inhibitors that target different domains of γ-secretase exhibit similar dose-response effects for both substrates, including rank order of inhibitor potencies and effective concentration ranges. For two inhibitors, modest differences in inhibitor dose responses toward Notch and APP were detected, suggesting that inhibitors might be identified that possess some discrimination in their ability to target alternative γ-secretase substrates. These findings also indicate that despite an overall conservation in inhibitor potencies toward different γ-secretase substrates, quantitative differences might exist that could be relevant for the development of therapeutically valuable substrate-specific inhibitors.
Footnotes
This work was supported by National Institutes of Health National Institute of General Medical Sciences [Grant GM087650]; Data Management Services contract HHSN2612008000016C; the Department of Biochemistry and Molecular Biology, Thomas Jefferson University; and the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
doi:10.1124/mol.109.062471.
-
ABBREVIATIONS:
- APP
- amyloid precursor protein
- Aβ42
- amyloid β42 peptide
- PS1
- Presenilin-1
- PS2
- Presenilin-2
- Aph-1
- anterior pharynx defective-1
- APPL
- amyloid precursor protein-like
- APLP
- amyloid precursor-like protein
- ADAM
- A Disintegrin And Metalloproteinase enzyme
- NTF
- N-terminal fragment
- CTF
- C-terminal fragment
- NICD
- Notch intracellular domain
- AICD
- amyloid precursor protein intracellular domain
- DFK167
- difluoro-ketone peptidomimetic inhibitor-167
- DAPT
- N-[N-(3,5-difluorophenylacetyl)-l-alanyl]-S-phenylglycine t-butyl ester
- CpnE
- compound E [(S,S)-2-[2-(3,5-difluorophenyl)acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide]
- DBZ
- dibenzazepine [(S,S)-2-[2-(3,5-difluorophenyl)acetylamino]-N-(5-methyl-6-oxo-6, 7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propionamide]
- BB94
- batimastat
- GM6001
- N-[(2R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl]-l-tryptophan methylamide
- Tricine
- N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.
- Received November 16, 2009.
- Accepted January 4, 2010.
- U.S. Government work not protected by U.S. copyright
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|